AGP Executive Report
Last update: an hour agoNew Treatment: The FDA approved Livsayis (cemdisiran) for adults with generalized myasthenia gravis, making it the first siRNA therapy for the condition and the only approved option given by injection four times a year. Vaccine Research: Krishnan Ramanathan, a former Novartis and J&J executive, will lead Gates Medical Research Institute as it advances a late-stage tuberculosis vaccine candidate. GLP-1 Safety: The FDA has required a warning about a rare eye condition on GLP-1 drug labels; links to other reported effects, including hair loss, remain uncertain. The agency has also sent dozens of warning letters over misleading claims that compounded versions match branded drugs. Drug Recall: Breckenridge Pharmaceutical recalled a lot of extended-release propranolol capsules over possible metal fragments. Patients should contact a pharmacist or clinician for advice. Measles: The U.S. has lost its measles-elimination status after a year of continuous transmission, underscoring the need to close vaccination gaps. Emerging Therapies: A phase 2 trial found mobility and disability improvements after a single CAR T-cell infusion in patients with stiff person syndrome. Everyday Health: A small trial suggests several short walks spread through the day may improve blood sugar regulation more than one daily walk.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.